Advancement of NF-κB signaling pathway: A novel target in pancreatic cancer

Kartick C. Pramanik, Monish Ram Makena, Kuntal Bhowmick, Manoj Pandey

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers and is the third highest among cancer related deaths. Despite modest success with therapy such as gemcitabine, pancreatic cancer incidence remains virtually unchanged in the past 25 years. Among the several driver mutations for PDAC, Kras mutation contributes a central role for its development, progression and therapeutic resistance. In addition, inflammation is implicated in the development of most human cancer, including pancreatic cancer. Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) is recognized as a key mediator of inflammation and has been frequently observed to be upregulated in PDAC. Several lines of evidence suggest that NF-κB pathways play a crucial role in PDAC development, progression and resistance. In this review, we focused on emphasizing the recent advancements in the involvement of NF-κB in PADC’s progression and resistance. We also highlighted the interaction of NF-κB with other signaling pathways. Lastly, we also aim to discuss how NF-κB could be an excellent target for PDAC prevention or therapy. This review could provide insight into the development of novel therapeutic strategies by considering NF-κB as a target to prevent or treat PDAC.

Original languageEnglish (US)
Article number3890
JournalInternational Journal of Molecular Sciences
Volume19
Issue number12
DOIs
StatePublished - Dec 1 2018

Fingerprint

gemcitabine
Pancreatic Neoplasms
Adenocarcinoma
cancer
Inflammation Mediators
progressions
mutations
Cells
therapy
Neoplasms
Mutation
death
Human Development
Therapeutics
incidence
B-Lymphocytes
Inflammation
Light
Incidence
interactions

All Science Journal Classification (ASJC) codes

  • Catalysis
  • Molecular Biology
  • Spectroscopy
  • Computer Science Applications
  • Physical and Theoretical Chemistry
  • Organic Chemistry
  • Inorganic Chemistry

Cite this

Pramanik, Kartick C. ; Makena, Monish Ram ; Bhowmick, Kuntal ; Pandey, Manoj. / Advancement of NF-κB signaling pathway : A novel target in pancreatic cancer. In: International Journal of Molecular Sciences. 2018 ; Vol. 19, No. 12.
@article{8e256b8b59234bfea655321584a21899,
title = "Advancement of NF-κB signaling pathway: A novel target in pancreatic cancer",
abstract = "Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers and is the third highest among cancer related deaths. Despite modest success with therapy such as gemcitabine, pancreatic cancer incidence remains virtually unchanged in the past 25 years. Among the several driver mutations for PDAC, Kras mutation contributes a central role for its development, progression and therapeutic resistance. In addition, inflammation is implicated in the development of most human cancer, including pancreatic cancer. Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) is recognized as a key mediator of inflammation and has been frequently observed to be upregulated in PDAC. Several lines of evidence suggest that NF-κB pathways play a crucial role in PDAC development, progression and resistance. In this review, we focused on emphasizing the recent advancements in the involvement of NF-κB in PADC’s progression and resistance. We also highlighted the interaction of NF-κB with other signaling pathways. Lastly, we also aim to discuss how NF-κB could be an excellent target for PDAC prevention or therapy. This review could provide insight into the development of novel therapeutic strategies by considering NF-κB as a target to prevent or treat PDAC.",
author = "Pramanik, {Kartick C.} and Makena, {Monish Ram} and Kuntal Bhowmick and Manoj Pandey",
year = "2018",
month = "12",
day = "1",
doi = "10.3390/ijms19123890",
language = "English (US)",
volume = "19",
journal = "International Journal of Molecular Sciences",
issn = "1661-6596",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "12",

}

Advancement of NF-κB signaling pathway : A novel target in pancreatic cancer. / Pramanik, Kartick C.; Makena, Monish Ram; Bhowmick, Kuntal; Pandey, Manoj.

In: International Journal of Molecular Sciences, Vol. 19, No. 12, 3890, 01.12.2018.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Advancement of NF-κB signaling pathway

T2 - A novel target in pancreatic cancer

AU - Pramanik, Kartick C.

AU - Makena, Monish Ram

AU - Bhowmick, Kuntal

AU - Pandey, Manoj

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers and is the third highest among cancer related deaths. Despite modest success with therapy such as gemcitabine, pancreatic cancer incidence remains virtually unchanged in the past 25 years. Among the several driver mutations for PDAC, Kras mutation contributes a central role for its development, progression and therapeutic resistance. In addition, inflammation is implicated in the development of most human cancer, including pancreatic cancer. Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) is recognized as a key mediator of inflammation and has been frequently observed to be upregulated in PDAC. Several lines of evidence suggest that NF-κB pathways play a crucial role in PDAC development, progression and resistance. In this review, we focused on emphasizing the recent advancements in the involvement of NF-κB in PADC’s progression and resistance. We also highlighted the interaction of NF-κB with other signaling pathways. Lastly, we also aim to discuss how NF-κB could be an excellent target for PDAC prevention or therapy. This review could provide insight into the development of novel therapeutic strategies by considering NF-κB as a target to prevent or treat PDAC.

AB - Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers and is the third highest among cancer related deaths. Despite modest success with therapy such as gemcitabine, pancreatic cancer incidence remains virtually unchanged in the past 25 years. Among the several driver mutations for PDAC, Kras mutation contributes a central role for its development, progression and therapeutic resistance. In addition, inflammation is implicated in the development of most human cancer, including pancreatic cancer. Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) is recognized as a key mediator of inflammation and has been frequently observed to be upregulated in PDAC. Several lines of evidence suggest that NF-κB pathways play a crucial role in PDAC development, progression and resistance. In this review, we focused on emphasizing the recent advancements in the involvement of NF-κB in PADC’s progression and resistance. We also highlighted the interaction of NF-κB with other signaling pathways. Lastly, we also aim to discuss how NF-κB could be an excellent target for PDAC prevention or therapy. This review could provide insight into the development of novel therapeutic strategies by considering NF-κB as a target to prevent or treat PDAC.

UR - http://www.scopus.com/inward/record.url?scp=85058392880&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058392880&partnerID=8YFLogxK

U2 - 10.3390/ijms19123890

DO - 10.3390/ijms19123890

M3 - Review article

C2 - 30563089

AN - SCOPUS:85058392880

VL - 19

JO - International Journal of Molecular Sciences

JF - International Journal of Molecular Sciences

SN - 1661-6596

IS - 12

M1 - 3890

ER -